This was the stock's third consecutive day of gains.
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
PARSIPPANY, N.J., February 20, 2025--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences.
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...
Shares of Zoetis ( ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback